The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
The clinical development of MEK inhibitors
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mammalian MAP kinase signalling cascades
Chang, L., & Karin, M. (2001) · Nature · doi:10.1038/35065000 · Cited by 5,111
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Cowley, S. (1994) · Cell · doi:10.1016/0092-8674(94)90133-3 · Cited by 1,966
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,831
Signal Transduction through MAP Kinase Cascades
(1998) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60765-4 · Cited by 1,759
ERK1/2 MAP kinases: Structure, function, and regulation
Roskoski, R. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,650
Research works printed but not linked: 11
- Mehra, R. et al. First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors [abstract]. J. Clin. Oncol. 30 (Suppl.), a3007 (2012). · doi:10.1200/jco.2012.30.15_suppl.3007
- Harding, J. J. et al. Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets) [abstract]. J. Clin. Oncol. 31 (Suppl.), a9060 (2013). · doi:10.1200/jco.2013.31.15_suppl.9060
- Jain, N, C. et al. Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML) [abstract]. J. Clin. Oncol. 30 (Suppl.), a6582 (2012).
- Hochster, H. S. et al. The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC) [abstract]. J. Clin. Oncol. 31 (Suppl.), a3587 (2013). · DOI
- Gupta, A. et al. DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma [abstract]. J. Clin. Oncol. 31 (Suppl.), a9068 (2013). · doi:10.1200/jco.2013.31.15_suppl.9068
- Rosen, L. S. et al. A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors [abstract]. J. Clin. Oncol. 26 (Suppl.), a14585 (2008). · doi:10.1200/jco.2008.26.15_suppl.14585
- Van Laethem, J. L. et al. A phase I/II study of the MEK inhibitor BAY 86-9766 (BAY) in combination with gemcitabine (GEM) in patients with nonresectable, locally advanced or metastatic pancreatic cancer (PC): phase I dose-escalation results [abstract]. J. Clin. Oncol. 30 (Suppl.), a4050 (2012). · doi:10.1200/jco.2012.30.15_suppl.4050
- Infante, J. R. et al. A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas [abstract]. J. Clin. Oncol. 30 (Suppl.), a291 (2013). · doi:10.1200/jco.2013.31.4_suppl.291
- Ahmed, S. R. et al. A phase I study determining the safety and tolerability of combination therapy with pazopanib, a VEGFR/PDGFR/raf inhibitor, and GSK1120212, a MEK inhibitor, in advanced solid tumors enriched with patients with advanced differentiated thyroid cancer [abstract]. J. Clin. Oncol. 30 (Suppl.), TPS3117 (2012). · doi:10.1200/jco.2012.30.15_suppl.tps3117
- Sosman, J. A. et al. First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma [abstract]. J. Clin. Oncol. 29 (Suppl.), TPS145 (2011). · doi:10.1200/jco.2011.29.15_suppl.tps145
- Adjei, A. A. et al. Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors [abstract]. J. Clin. Oncol. 31 (Suppl.), a2528 (2013). · doi:10.1200/jco.2013.31.15_suppl.2528
Cited by
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Jia, Y., Yun, C.-H., Park, E., Ercan, D., Manuia, M., Juarez, J., Xu, C., Rhee, K., Chen, T., Zhang, H., et al. (2016) · Nature · doi:10.1038/nature17960 · Cited by 886
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606
Garbe, C., Peris, K., Hauschild, A., Saiag, P., Middleton, M., Bastholt, L., Grob, J.-J., Malvehy, J., Newton-Bishop, J., Stratigos, A. J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.05.005 · Cited by 605
Bauer, R. A. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.05.005 · Cited by 534
Somatic Activating KRAS Mutations in Arteriovenous Malformations of the Brain
Nikolaev, S. I., Vetiska, S., Bonilla, X., Boudreau, E., Jauhiainen, S., Rezai Jahromi, B., Khyzha, N., DiStefano, P. V., Suutarinen, S., Kiehl, T.-R., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709449 · Cited by 467
Therapeutic strategies to target RAS-mutant cancers
Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420
Combine and conquer: challenges for targeted therapy combinations in early phase trials
Lopez, J. S., & Banerji, U. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.96 · Cited by 394
The ERK and JNK pathways in the regulation of metabolic reprogramming
Papa, S., Choy, P. M., & Bubici, C. (2019) · Oncogene · doi:10.1038/s41388-018-0582-8 · Cited by 381
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
Mainardi, S., Mulero-Sánchez, A., Prahallad, A., Germano, G., Bosma, A., Krimpenfort, P., Lieftink, C., Steinberg, J. D., de Wit, N., Gonçalves-Ribeiro, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0023-9 · Cited by 320
Targeting ERK1/2 protein-serine/threonine kinases in human cancers
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.039 · Cited by 308
Current Development Status of MEK Inhibitors
Cheng, Y., & Tian, H. (2017) · Molecules · doi:10.3390/molecules22101551 · Cited by 291
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
Ambrogio, C., Köhler, J., Zhou, Z.-W., Wang, H., Paranal, R., Li, J., Capelletti, M., Caffarra, C., Li, S., Lv, Q., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.020 · Cited by 270
“Small-molecule compounds targeting the MAPK pathway—one of the most prominent KRAS downstreammediators—have been developed (Zhao and Adjei, 2014); however, they show minimal clinical efficacy in KRAS mutant LUAD either as single agents or in combination with chemotherapy (Blumenschein et al.”
BackgroundRAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancer
Hrustanovic, G., Olivas, V., Pazarentzos, E., Tulpule, A., Asthana, S., Blakely, C. M., Okimoto, R. A., Lin, L., Neel, D. S., Sabnis, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3930 · Cited by 267
Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials
Song, Y., Bi, Z., Liu, Y., Qin, F., Wei, Y., & Wei, X. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.05.006 · Cited by 212
MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer
Zhan, T., Ambrosi, G., Wandmacher, A. M., Rauscher, B., Betge, J., Rindtorff, N., Häussler, R. S., Hinsenkamp, I., Bamberg, L., Hessling, B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09898-0 · Cited by 189
Structural basis for the action of the drug trametinib at KSR-bound MEK
Khan, Z. M., Real, A. M., Marsiglia, W. M., Chow, A., Duffy, M. E., Yerabolu, J. R., Scopton, A. P., & Dar, A. C. (2020) · Nature · doi:10.1038/s41586-020-2760-4 · Cited by 178
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Aguirre, A. J., & Hahn, W. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031518 · Cited by 90
“Unfortunately, clinical trials testing single agent inhibition of the critical KRAS effectors (e.g. MAPK or PI3K) in KRAS-mutant cancers have been disappointing to date (Adjei et al. 2008; Infante et al. 2012; Infante et al. 2013; Zhao and Adjei 2014).”
BackgroundMEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity
Duncan, K. E., Chang, L. Y., & Patronas, M. (2015) · Eye · doi:10.1038/eye.2015.82 · Cited by 87
MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects
Urner-Bloch, U., Urner, M., Jaberg-Bentele, N., Frauchiger, A. L., Dummer, R., & Goldinger, S. M. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.018 · Cited by 82
Simpkins, F., Jang, K., Yoon, H., Hew, K. E., Kim, M., Azzam, D. J., Sun, J., Zhao, D., Ince, T. A., Liu, W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3697 · Cited by 67
Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer
Li, S., Liu, S., Deng, J., Akbay, E. A., Hai, J., Ambrogio, C., Zhang, L., Zhou, F., Jenkins, R. W., Adeegbe, D. O., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3438 · Cited by 67
YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling
Coggins, G. E., Farrel, A., Rathi, K. S., Hayes, C. M., Scolaro, L., Rokita, J. L., & Maris, J. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1415 · Cited by 66
Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
Solimando, A. G., Malerba, E., Leone, P., Prete, M., Terragna, C., Cavo, M., & Racanelli, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.973836 · Cited by 65
“The biological role of the RAF/RAS pathway in the BM microenvironment (99) led to investigations into the role of RAS in MM.”
BackgroundWang, J., Martin-Romano, P., Cassier, P., Johnson, M., Haura, E., Lenox, L., Guo, Y., Bandyopadhyay, N., Russell, M., Shearin, E., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyab080 · Cited by 60
Kirouac, D. C., Schaefer, G., Chan, J., Merchant, M., Orr, C., Huang, S.-M. A., Moffat, J., Liu, L., Gadkar, K., & Ramanujan, S. (2017) · npj Systems Biology and Applications · doi:10.1038/s41540-017-0016-1 · Cited by 60
Zaanan, A., Okamoto, K., Kawakami, H., Khazaie, K., Huang, S., & Sinicrope, F. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.657833 · Cited by 59
Ocular Safety Profile of BRAF and MEK Inhibitors
Mettler, C., Monnet, D., Kramkimel, N., Tréluyer, J.-M., Mouthon, L., Brézin, A., Dupin, N., Valnet-Rabier, M.-B., Chouchana, L., & Terrier, B. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.05.008 · Cited by 40
Ferrous iron–activatable drug conjugate achieves potent MAPK blockade in KRAS -driven tumors
Jiang, H., Muir, R. K., Gonciarz, R. L., Olshen, A. B., Yeh, I., Hann, B. C., Zhao, N., Wang, Y.-H., Behr, S. C., Korkola, J. E., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20210739 · Cited by 33
“Moreover, single-agent inhibition of KRAS effectors (e.g., MEK-MAPK pathway) in KRAS - mutant cancers has been disappointing to date (Adjei et al., 2008; Infante et al., 2012; Ko et al., 2016; Zhao and Adjei, 2014).”
Kang, D., Wang, Y., Lin, Y., Ma, W. W., Morgensztern, D., Leventakos, K., Bi, C., Ding, Y., Xiong, J., Yan, M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3691 · Cited by 17
Inhibition of MEK1 signaling pathway in the liver ameliorates insulin resistance
Ueyama, A., Ban, N., Fukazawa, M., Hirayama, T., Takeda, M., Yata, T., Muramatsu, H., Hoshino, M., Yamamoto, M., Matsuo, M., et al. (2016) · Journal of Diabetes Research · doi:10.1155/2016/8264830 · Cited by 7
“The therapeutic potential of MEK inhibition needs to be examined in clinical trials with T2D patients, and further study is needed to explore the exact mechanisms through which inhibiting the MEK1 signaling pathway improves IR, especially in the liver, in order to avoid undesirable adverse events by MEK inhibition [37…”
Ji, X., Yun, Y., Zhu, Z., Wu, T., Ruan, M., Fan, Y., & Zhang, Q. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04266-7
“For instance, MEK inhibitors, which are clinically approved for other malignancies, could be effective in ccRCC tumors characterized by high PPP1R18 expression [63].”
Metadata
- Authors
- Zhao, Y., & Adjei, A. A.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2014-05-20
- Volume
- 11
- Issue
- 7
- Pages
- 385-400
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W1991401350
- Cited by
- 400
- References
- 126
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.